glp-1 obesity drugs news today 2025 Pharmacy Pricing Update (Dec 2025) glp-1 obesity drug news today

In consideration of the reduced compliance of peptide GLP-1 receptor agonists due to subcutaneous injection, oral micromolecular GLP-1 receptor agonists such as orforglipron have already in clinical trials, which can reduce body weight and improve cardiac metabolism in adults with obesity (Wharton et al 2023) (Fig

However, these drugs are known to cause a plethora of adverse effects such as weight gain, edema, intestinal discomfort and hypoglycemia (2)

Why choose BHH for GLP-1 Plus

Increasing data are showing that weight loss with these medications has increased fertility

This AA-mediated mechanism is enhanced by peroxidation of AA leading to the formation of AA metabolites such as -KA

October 15, 2025: 133 New Lawsuits Filed for Injuries from Zepbound and Other GLP-1 Drugs Between September and October 2025, 133 lawsuits joined the group litigation for people harmed by Zepbound and other GLP-1 drugs